High RPMB predicts poor disease-free survival of male N1 papillary thyroid cancer after adjuvant radioiodine therapy

The current recommendation for the use of adjuvant radioactive iodine (RAI) therapy in papillary thyroid cancer (PTC) after radical surgery is based on clinicopathological factors; however, this recommendation remains controversial. Our present study established a new biomarker, RPMB (promotor methy...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Ning, Yang, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708696/
https://www.ncbi.nlm.nih.gov/pubmed/36468103
http://dx.doi.org/10.1016/j.heliyon.2022.e11783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708696/
https://www.ncbi.nlm.nih.gov/pubmed/36468103
http://dx.doi.org/10.1016/j.heliyon.2022.e11783

Ejemplares similares